News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,737 Results
Type
Article (43441)
Company Profile (347)
Press Release (667949)
Section
Business (211987)
Career Advice (2163)
Deals (37032)
Drug Delivery (103)
Drug Development (83924)
Employer Resources (173)
FDA (16610)
Job Trends (15526)
News (359191)
Policy (34331)
Tag
Academia (2608)
Alliances (51693)
Alzheimer's disease (1250)
Approvals (16521)
Artificial intelligence (139)
Bankruptcy (368)
Best Places to Work (11721)
Biotechnology (221)
Breast cancer (118)
Cancer (1058)
Cardiovascular disease (91)
Career advice (1801)
Cell therapy (224)
Clinical research (66510)
Collaboration (372)
Compensation (190)
COVID-19 (2620)
Data (1014)
Diabetes (157)
Diagnostics (6238)
Drug pricing (96)
Earnings (86775)
Employer resources (152)
Events (113290)
Executive appointments (281)
FDA (17109)
Funding (328)
Gene therapy (177)
GLP-1 (641)
Government (4510)
Healthcare (18990)
Infectious disease (2707)
Inflammatory bowel disease (109)
Interviews (337)
IPO (16715)
Job creations (4156)
Job search strategy (1548)
Layoffs (447)
Legal (8460)
Lung cancer (169)
Manufacturing (179)
Medical device (13299)
Medtech (13304)
Mergers & acquisitions (20353)
Metabolic disorders (437)
Neuroscience (1520)
NextGen Class of 2024 (6713)
Non-profit (4538)
Northern California (1384)
Obesity (258)
Opinion (222)
Patents (104)
People (58664)
Pharmaceutical (101)
Phase I (20670)
Phase II (29220)
Phase III (21915)
Pipeline (373)
Postmarket research (2673)
Preclinical (8741)
Radiopharmaceuticals (243)
Rare diseases (213)
Real estate (6347)
Regulatory (22656)
Research institute (2381)
Resumes & cover letters (370)
Southern California (1225)
Startups (3778)
United States (12963)
Vaccines (575)
Weight loss (207)
Date
Today (229)
Last 7 days (1016)
Last 30 days (3612)
Last 365 days (36335)
2024 (32556)
2023 (40929)
2022 (52113)
2021 (56676)
2020 (55113)
2019 (47824)
2018 (36140)
2017 (33571)
2016 (33171)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30873)
2010 (28892)
Location
Africa (804)
Arizona (199)
Asia (40914)
Australia (6485)
California (3118)
Canada (1242)
China (242)
Colorado (134)
Connecticut (144)
Europe (87486)
Florida (432)
Georgia (109)
Illinois (341)
Indiana (200)
Kansas (96)
Maryland (567)
Massachusetts (2517)
Michigan (152)
Minnesota (265)
New Jersey (914)
New York (911)
North Carolina (725)
Northern California (1384)
Ohio (135)
Pennsylvania (806)
South America (1179)
Southern California (1225)
Texas (436)
Washington State (352)
711,737 Results for "plx pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
PLx Pharma Inc. Receives Nasdaq Delisting Notice - April 11, 2023
PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.
April 11, 2023
·
4 min read
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Pharm Country
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.
April 12, 2023
·
4 min read
Drug Development
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial investigating PLX038 (PEG~SN-38) for locally-advanced or metastatic triple-negative breast cancer (TNBC).
March 25, 2024
·
2 min read
Business
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.First Commercial Agreement for DispersinB®
Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.
June 25, 2024
·
3 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
Press Releases
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
November 8, 2024
·
12 min read
Pharm Country
Mitsubishi Tanabe Pharma America, Inc. (MTPA) Stands with the ALS Community
Mitsubishi Tanabe Pharma America, Inc. is aware of recent external challenges facing the amyotrophic lateral sclerosis treatment landscape.
May 23, 2024
·
6 min read
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
Pluri Inc. announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University.
December 21, 2023
·
7 min read
Press Releases
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927
November 5, 2024
·
1 min read
1 of 71,174
Next
